Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Nov 1;105(3):890–897. doi: 10.1210/clinem/dgz163

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Endocrine Society 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com

This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)

PMC Copyright notice

Figure 2. — Cumulative relative frequency distribution plots of percent change in bone mineral density from baseline to 9 and 15 months. ^aBMD, bone mineral density; HD, high-dose teriparatide (40 μg) plus denosumab; SD, standard-dose teriparatide (20 μg) plus denosumab.

^aIncludes 60 participants who had areal bone mineral density (aBMD) determinations at all study visits (baseline, month 9, and month 15, 79% of the DATA-HD population at enrollment). Data missing for 1 participant in the SD group for femoral neck aBMD at 9 and 15 months and 2 participants in the SD group and 2 participants in the HD group for lumbar spine aBMD at 9 and 15 months.